Suman Mewa Kinoo1,2, Anil A Chuturgoon1, Bugwan Singh2, Savania Nagiah3,4. 1. Department of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Science, University of KwaZulu Natal, Durban, Glenwood, 4041, South Africa. 2. Discipline of General Surgery, School of Clinical Medicine, College of Health Science, University of KwaZulu Natal, Umbilo, Durban, 4001, South Africa. 3. Department of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Science, University of KwaZulu Natal, Durban, Glenwood, 4041, South Africa. savanian@mandela.ac.za. 4. Present address: Department of Human Biology, Medical Programme, Faculty of Health Sciences, Nelson Mandela University Missionvale Campus, Room 113, 2nd floor, Road, Salt Pan, Bethelsdorp, Port Elizabeth, 6059, South Africa. savanian@mandela.ac.za.
Abstract
BACKGROUND: HIV endemic populations are displaying higher incidence of metabolic disorders. HIV and the standard treatment are both associated with altered lipid and cholesterol metabolism, however gallstone disease (a cholesterol related disorder) in Sub-Saharan African populations is rarely investigated. METHODS: This study sought to evaluate hepatic expression of key genes in cholesterol metabolism (LDLr, HMGCR, ABCA1) and transcriptional regulators of these genes (microRNA-148a, SREBP2) in HIV positive patients on antiretroviral therapy presenting with gallstones. Liver biopsies from HIV positive patients (cases: n = 5) and HIV negative patients (controls: n = 5) were analysed for miR-148a and mRNA expression using quantitative PCR. RESULTS: Circulating total cholesterol was elevated in the HIV positive group with significantly elevated LDL-c levels(3.16 ± 0.64 mmol/L) relative to uninfected controls (2.10 ± 0.74 mmol/L; p = 0.04). A scavenging receptor for LDL-c, LDLr was significantly decreased (0.18-fold) in this group, possibly contributing to higher LDL-c levels. Transcriptional regulator of LDLr, SREBP2 was also significantly lower (0.13-fold) in HIV positive patients. Regulatory microRNA, miR-148a-3p, was reduced in HIV positive patients (0.39-fold) with a concomitant increase in target ABCA1 (1.5-fold), which regulates cholesterol efflux. CONCLUSIONS: Collectively these results show that HIV patients on antiretroviral therapy display altered hepatic regulation of cholesterol metabolizing genes, reducing cholesterol scavenging, and increasing cholesterol efflux.
BACKGROUND:HIV endemic populations are displaying higher incidence of metabolic disorders. HIV and the standard treatment are both associated with altered lipid and cholesterol metabolism, however gallstone disease (a cholesterol related disorder) in Sub-Saharan African populations is rarely investigated. METHODS: This study sought to evaluate hepatic expression of key genes in cholesterol metabolism (LDLr, HMGCR, ABCA1) and transcriptional regulators of these genes (microRNA-148a, SREBP2) in HIV positive patients on antiretroviral therapy presenting with gallstones. Liver biopsies from HIV positive patients (cases: n = 5) and HIV negative patients (controls: n = 5) were analysed for miR-148a and mRNA expression using quantitative PCR. RESULTS: Circulating total cholesterol was elevated in the HIV positive group with significantly elevated LDL-c levels(3.16 ± 0.64 mmol/L) relative to uninfected controls (2.10 ± 0.74 mmol/L; p = 0.04). A scavenging receptor for LDL-c, LDLr was significantly decreased (0.18-fold) in this group, possibly contributing to higher LDL-c levels. Transcriptional regulator of LDLr, SREBP2 was also significantly lower (0.13-fold) in HIV positive patients. Regulatory microRNA, miR-148a-3p, was reduced in HIV positive patients (0.39-fold) with a concomitant increase in target ABCA1 (1.5-fold), which regulates cholesterol efflux. CONCLUSIONS: Collectively these results show that HIVpatients on antiretroviral therapy display altered hepatic regulation of cholesterol metabolizing genes, reducing cholesterol scavenging, and increasing cholesterol efflux.
Entities:
Keywords:
ABCA1; Cholelithiasis; Cholesterol; Gall stone; HIV; LDLr; miR-148a
Authors: J M Petit; M Duong; L Duvillard; E Florentin; H Portier; G Lizard; J M Brun; P Gambert; B Verges Journal: Eur J Clin Invest Date: 2002-05 Impact factor: 4.686
Authors: D W Lee; C J Gilmore; G Bonorris; H Cohen; J W Marks; M Cho-Sue; M S Meiselman; L J Schoenfield Journal: Am J Clin Nutr Date: 1985-09 Impact factor: 7.045
Authors: Huanhuan L Cui; Angela Grant; Nigora Mukhamedova; Tatiana Pushkarsky; Lucas Jennelle; Larisa Dubrovsky; Katharina Gaus; Michael L Fitzgerald; Dmitri Sviridov; Michael Bukrinsky Journal: J Lipid Res Date: 2012-01-19 Impact factor: 5.922
Authors: Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna Journal: Int J Mol Sci Date: 2022-05-17 Impact factor: 6.208